Third Harmonic Bio, Inc. (THRD)
Market Cap | 506.91M |
Revenue (ttm) | n/a |
Net Income (ttm) | -39.20M |
Shares Out | 45.06M |
EPS (ttm) | -0.97 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 303,450 |
Open | 11.56 |
Previous Close | 11.83 |
Day's Range | 10.97 - 11.64 |
52-Week Range | 8.08 - 16.94 |
Beta | 2.66 |
Analysts | Strong Buy |
Price Target | 20.33 (+80.71%) |
Earnings Date | Nov 7, 2024 |
About THRD
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc.... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for THRD stock is "Strong Buy." The 12-month stock price forecast is $20.33, which is an increase of 80.71% from the latest price.
News
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respirat...
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respirat...
Third Harmonic Bio Announces Third Quarter 2024 Financial Results
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANC...
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respira...
Third Harmonic Bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respirat...
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $255.3 million as of June 3...
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respirato...
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H'25 Strengthened leadership tea...
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today a...
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, Mar...
Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today an...
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H'24
Third Harmonic Bio Announces Leadership Changes
SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today an...
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today an...
Third Harmonic Bio Announces Second Quarter 2023 Financial Results
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distrib...
Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335
THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical profile
Third Harmonic Bio Announces First Quarter 2023 Financial Results
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated ...
Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated ...
Top 5 Health Care Stocks That May Rally - AstraZeneca (NASDAQ:AZN), Amgen (NASDAQ:AMGN)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
5 Cheapest Health Care Stocks You Should Think About
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
5 Cheapest Health Care Stocks You Should Think About - Baxter Intl (NYSE:BAX), Cutera (NASDAQ:CUTR)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Third Harmonic's stock falls 75% after discontinuing clinical trial
Shares of Third Harmonic Bio Inc. tumbled 75% in premarket trading on Thursday after the company said it discontinued the Phase 1b study of its treatment for chronic inducible urticaria, a common infl...
Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria
-- Company decision follows observation of asymptomatic liver transaminitis in two subjects enrolled in first dose cohort of 200mg BID